A clinical trial of adjunctive oestrogen treatment in women with schizophrenia

Jayashiri Kulkarni, A. Riedel, A. R. De Castella, P. B. Fitzgerald, T. J. Rolfe, J. Taffe, H. Burger

Research output: Contribution to journalArticleResearchpeer-review

57 Citations (Scopus)


A double-blind, 28-day, placebo-controlled study was conducted with three groups of women of child-bearing age (N = 12 in each group) who received standardised antipsychotic medication plus a) 50 μg transdermal estradiol or b) 100 μg transdermal estradiol or c) transdermal placebo. Preliminary analyses show that women receiving 100 μg of estradiol made greater improvements in the symptoms of schizophrenia than either the 50 μg estradiol or placebo groups. The addition of 100 μg adjunctive transdermal oestrogen significantly enhanced treatment responsivity of acute, severe psychotic symptoms in women with schizophrenia. The positive impact of oestrogen treatment on psychotic symptoms via a multiplicity of possible actions (see accompanying articles in this issue) may prove clinically useful in the overall treatment of women with schizophrenia.

Original languageEnglish
Pages (from-to)99-104
Number of pages6
JournalArchives of Women's Mental Health
Issue number3
Publication statusPublished - 1 Nov 2002


  • Dopamine
  • Oestrogen/estrogen
  • Prolactin
  • Schizophrenia
  • Serotonin

Cite this